Correlation of CYP2C19 genotype with plasma voriconazole exposure in South-western Chinese Han patients with invasive fungal infections
作者： Qiang Miao , Jiang-Tao Tang , Teun van Gelder , Ya-Mei Li , Yang-Juan Bai
DOI: 10.1097/MD.0000000000014137
关键词:
摘要: AbstractThe aim of this study was to investigate the correlation between CYP2C19 genotype and dose-adjusted voriconazole (VCZ) trough concentrations (C0/dose).We analyzed CYP2C19*2(681G>A), CYP2C19*3(636G>A), CYP2C19*17(-806C>T) genetic polymorphisms dose-correcte
lww.com
sci-hub.se 参考文章(32)
Joachim D. Weigel, Nicole G. M. Hunfeld, Birgit C. P. Koch, Mohamud Egal, Jan Bakker, Ron H. N. van Schaik, Teun van Gelder, Gain-of-function single nucleotide variants of the CYP2C19 gene (CYP2C19*17) can identify subtherapeutic voriconazole concentrations in critically ill patients: a case series. Intensive Care Medicine. ,vol. 41, pp. 2013- 2014 ,(2015) , 10.1007/S00134-015-4002-Z
Hyewon Chung, Howard Lee, HyeKyung Han, Hyungmi An, Kyoung Soo Lim, YongJin Lee, Joo-Youn Cho, Seo Hyun Yoon, In-Jin Jang, Kyung-Sang Yu, A pharmacokinetic comparison of two voriconazole formulations and the effect of CYP2C19 polymorphism on their pharmacokinetic profiles. Drug Design Development and Therapy. ,vol. 9, pp. 2609- 2616 ,(2015) , 10.2147/DDDT.S80066
Ina Scholz, Heike Oberwittler, Klaus-Dieter Riedel, Jürgen Burhenne, Johanna Weiss, Walter E. Haefeli, Gerd Mikus, Pharmacokinetics, metabolism and bioavailability of the triazole antifungal agent voriconazole in relation to CYP2C19 genotype. British Journal of Clinical Pharmacology. ,vol. 68, pp. 906- 915 ,(2009) , 10.1111/J.1365-2125.2009.03534.X
Lingling Chen, Shengying Qin, Jing Xie, Jimin Tang, Lun Yang, Wen Shen, Xinzhi Zhao, Jing Du, Guang He, Guoyin Feng, Lin He, Qinghe Xing, Genetic polymorphism analysis of CYP2C19 in Chinese Han populations from different geographic areas of mainland China Pharmacogenomics. ,vol. 9, pp. 691- 702 ,(2008) , 10.2217/14622416.9.6.691
Atsushi Narita, Hideki Muramatsu, Hirotoshi Sakaguchi, Sayoko Doisaki, Makito Tanaka, Asahito Hama, Akira Shimada, Yoshiyuki Takahashi, Nao Yoshida, Kimikazu Matsumoto, Koji Kato, Kazuko Kudo, Yoko Furukawa-Hibi, Kiyofumi Yamada, Seiji Kojima, Correlation of CYP2C19 Phenotype With Voriconazole Plasma Concentration in Children Journal of Pediatric Hematology/Oncology. ,vol. 35, pp. e219- e223 ,(2013) , 10.1097/MPH.0B013E3182880EAA
SeungHwan Lee, Bo-Hyung Kim, Won-Seok Nam, Seo Hyun Yoon, Joo-Youn Cho, Sang-Goo Shin, In-Jin Jang, Kyung-Sang Yu, Effect of CYP2C19 polymorphism on the pharmacokinetics of voriconazole after single and multiple doses in healthy volunteers. The Journal of Clinical Pharmacology. ,vol. 52, pp. 195- 203 ,(2012) , 10.1177/0091270010395510
Michael J. Dolton, John E. Ray, Sharon C.-A. Chen, Kingsley Ng, Lisa G. Pont, Andrew J. McLachlan, Multicenter Study of Voriconazole Pharmacokinetics and Therapeutic Drug Monitoring Antimicrobial Agents and Chemotherapy. ,vol. 56, pp. 4793- 4799 ,(2012) , 10.1128/AAC.00626-12
H.-R. He, J.-Y. Sun, X.-D. Ren, T.-T. Wang, Y.-J. Zhai, S.-Y. Chen, Y.-L. Dong, J. Lu, Effects of CYP3A4 polymorphisms on the plasma concentration of voriconazole. European Journal of Clinical Microbiology & Infectious Diseases. ,vol. 34, pp. 811- 819 ,(2015) , 10.1007/S10096-014-2294-5
Alain Li-Wan-Po, Thierry Girard, Peter Farndon, Candy Cooley, James Lithgow, Pharmacogenetics of CYP2C19: functional and clinical implications of a new variant CYP2C19*17 British Journal of Clinical Pharmacology. ,vol. 69, pp. 222- 230 ,(2010) , 10.1111/J.1365-2125.2009.03578.X
Johanna Weiss, Magdalena Maria ten Hoevel, Jürgen Burhenne, Ingeborg Walter-Sack, Michael Marcus Hoffmann, Jens Rengelshausen, Walter E. Haefeli, Gerd Mikus, CYP2C19Genotype Is a Major Factor Contributing to the Highly Variable Pharmacokinetics of Voriconazole The Journal of Clinical Pharmacology. ,vol. 49, pp. 196- 204 ,(2009) , 10.1177/0091270008327537